September 19, 2025Thoracic CancerOpen Access

Real‐World Evidence That Non‐Smokers With High PD‐L1 Non‐Squamous NSCLC Have Poorer Outcomes With Immune Checkpoint Inhibitors

View Full Paper

Ask AI

Bookmark

Non-smokers with high PD-L1 non-squamous NSCLC show significantly poorer outcomes with immune checkpoint inhibitors.
Smokers had a higher partial response rate of 66.7%, compared to 25.0% in non-smokers, highlighting a stark difference in treatment effectiveness.
Chemoimmunotherapy significantly prolonged progression-free survival in non-smokers compared with ICI monotherapy, indicating a potentially better treatment approach.
Smoking status was found to independently predict better overall and progression-free survival, serving as a relevant stratification factor in treatment decisions.

Discussion

No takes yet. Share an insight, caveat, or question.

Retrospective analysis reveals poor outcomes for non-smokers with NSCLC and high PD-L1, suggesting chemoimmunotherapy may be advantageous.

Kuo et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Retrospective analysis reveals poor outcomes for non-smokers with NSCLC and high PD-L1, suggesting chemoimmunotherapy may be advantageous.